Can mRCC Patients Be Spared Debulking Nephrectomy?

In this video, Dr. Daniel George discusses CARMENA, which asked if cytoreductive surgery is necessary in the age of active systemic therapy for mRCC.

Related Content:

American Society of Clinical Oncology Annual Meeting (ASCO)Conference

Pembrolizumab and Etoposide Continue to Demonstrate Clinically Meaningful Survival Benefit in Untreated ES-SCLC

Frontline Tremelimumab/Durvalumab Combo Shows Promising Survival Benefit in Hard-to-Treat Subgroups of mNSCLC

Neoadjuvant Nivolumab/Chemo Demonstrates Superiority Vs Chemo Alone in Resectable Stage IIIA/B NSCLC